Connor, Clark & Lunn Investment Management Ltd. Celldex Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.8 Billion
Q1 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 8,158 shares of CLDX stock, worth $301,927. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,158

Previous 28,538 71.41%

Holding current value

$301,927

Previous $1.13 Million 69.76%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	SELL	$35.22 - $51.88 $717,783 - $1.06 Million	-20,380 Reduced 71.41%	8,158 $342,000
Q4 2023 Feb 09, 2024	BUY	$22.61 - $40.65 $234,759 - $422,068	10,383 Added 57.19%	28,538 $1.13 Million
Q3 2023 Nov 13, 2023	BUY	$25.45 - $37.46 $462,044 - $680,086	18,155 New	18,155 $499,000
Q1 2023 May 09, 2023	SELL	$34.78 - $47.43 $531,229 - $724,445	-15,274 Reduced 26.38%	42,636 $1.53 Million
Q4 2022 Feb 10, 2023	SELL	$27.78 - $45.38 $631,717 - $1.03 Million	-22,740 Reduced 28.2%	57,910 $2.58 Million

Q3 2022 Nov 10, 2022	BUY	$22.7 - $37.57 $1.83 Million - $3.03 Million	80,650 New	80,650 $2.27 Million
Q4 2021 Feb 10, 2022	SELL	$35.68 - $56.27 $432,334 - $681,823	-12,117 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$28.95 - $55.99 $69,943 - $135,271	-2,416 Reduced 16.62%	12,117 $654,000
Q2 2021 Aug 12, 2021	BUY	$20.71 - $35.37 $300,978 - $514,032	14,533 New	14,533 $486,000
Q1 2021 May 13, 2021	SELL	$16.19 - $29.91 $604,631 - $1.12 Million	-37,346 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$14.99 - $22.75 $213,352 - $323,800	-14,233 Reduced 27.59%	37,346 $654,000
Q3 2020 Nov 12, 2020	BUY	$9.65 - $15.19 $497,737 - $783,485	51,579 New	51,579 $765,000

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

61.2M

Call Options Held

291K

Put Options Held

246K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.73B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Celldex Therapeutics, Inc. Transaction History